View Larger Image Emergent Biosolutions shares plunge more than 38% after U.S. cancels deal with Covid vaccine maker The company will forgo $180 million due to the contract’s termination, executives told investors on a call. Read More By David Hilbern|2021-11-05T15:24:53-05:00November 5, 2021|Bankruptcy|Comments Off on Emergent Biosolutions shares plunge more than 38% after U.S. cancels deal with Covid vaccine maker Share This Story, Choose Your Platform! FacebookTwitterLinkedInEmail About the Author: David Hilbern Related Posts Morgan Stanley says Biden-backed green subsidies will boost this little-known hydrogen stock February 8, 2023 Manhattan rents hit an all-time high in January February 8, 2023 Market veteran is still bullish on tech despite earnings upset, and reveals his other top picks February 6, 2023